Ischemix, LLC   Report issue

For profit Phase 2
Founded: Maynard MA United States (1999)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2010
NCT00984802
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

cmx-2043 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angina, Unstable (Phase 2)

Coronary Artery Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1